In Vitro Models of Liver and Pancreatic Cancer

NCT02436564 | Unknown

• 1 other identifier: A093484
• Study Type: observational
• Target: 75
• Locations: 1 country
• Sites: 1

Brief Summary

The primary objective is to develop an in vitro model of cancer for laboratory study using liver, biliary and pancreatic cancer tissue. The secondary objective is to study the genetic and cellular biology of cancer of the liver, biliary tract and the pancreas. As well the investigators hope to compare molecular and cellular biology of cancer cells with normal cells as well as potentially test the efficacy of current and future anti-cancer therapies. Samples will be collected from tissue that has been resected as part of the treatment for a patient diagnosed with liver, bile duct or pancreas cancer.

Conditions

Cholangiocarcinoma; Hepatocellular Carcinoma; Pancreatic Neoplasm

Keywords

pancreas; stem cells; tumours; in vitro models; organoids; cancer,; bile duct; liver

Outcome Measures

Primary Outcomes (1)

• Number of tumour-derived organoids successfully cultured in vitro for a minimum of 3 months.

  3 years

Secondary Outcomes (1)

• Proportion of tumour-derived organoids that are genetically identical to the source tumour.

  3 years

Interventions

Organoid in vitro culture GENETIC

Generation of 'organoids' using in vitro culture techniques, genomic DNA and RNA sequencing, application of genome editing technology, investigation of anti-tumour drugs, investigation of biological and functional properties of tumour cells, transplantation of organoid lines into animal models.

Eligibility Criteria

• Age: 18 Years - 90 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients who are undergoing surgical resenctions of liver, biliary or pancreas cancers that are able to give informed consent

You may qualify if:

• All adult patients undergoing surgical resections for liver, biliary or pancreas cancers that are able to give informed consent.

You may not qualify if:

• Patients aged \<18 or those who are unable to give informed consent.

Sponsors & Collaborators

• Cambridge University Hospitals NHS Foundation Trust: lead
• The Gurdon Institute: collaborator
• Ann McLaren Laboratory of Regenerative Medicine: collaborator

Study Sites (1)

Addenbrooke's Hospital

Cambridge, CB2 0QQ, United Kingdom

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

fresh tissue, frozen tissue

MeSH Terms

Conditions

Cholangiocarcinoma; Carcinoma, Hepatocellular; Pancreatic Neoplasms; Neoplasms

Condition Hierarchy (Ancestors)

Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Liver Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Digestive System Diseases; Liver Diseases; Endocrine Gland Neoplasms; Pancreatic Diseases; Endocrine System Diseases

Study Officials

• Kourosh Saeb-Parsy, PhD, FRCS

  Cambridge Univeristy Hospitals

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Kourosh Saeb-Parsy, PhD, FRCS

CONTACT

(+44 1223 7) 68456; ks10014@cam.ac.uk

Nikitas Georgakopoulos, BSc

CONTACT

07554003700; ng395@cam.ac.uk

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: University Lecturer and Consulatan Transplant Surgeon

Study Record Dates

• First Submitted: April 30, 2015
• First Posted: May 7, 2015
• Study Start: July 1, 2015
• Primary Completion: September 1, 2018
• Last Updated: July 14, 2016

Record last verified: 2016-07

Locations

GB (1)